Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
For companies pursuing an orphan drug, successfully traversing the path to regulatory submission requires striking the right balance of speed-to-clinic and cost. While there is no one-size-fits-all approach, shared characteristics of successful development projects include:
In this whitepaper, our experts help guide you through the complex challenges of getting your small molecule orphan drug to market faster.